Focus: Novartis is a global pharmaceutical giant with 78,000 employees headquartered in Basel, Switzerland, competing across oncology, immunology, neuroscience, cardiovascular, and ophthalmology. The company maintains a diversified portfolio spanning small molecules, vaccines, and biologics.
Profile data last refreshed 21h ago · AI intelligence enriched 3w ago
Hot — 1287 jobs added in 30d
Net +426 (1287 new, 861 removed). Aggressive expansion phase.
5 recent layoff filings (12 mo) — 686 affected
Source: state DOL filings via Big Local News
Novartis offers prestige, scale, and innovation access but requires tolerance for frequent restructuring; ideal for commercially-minded professionals or those seeking stable, long-tenure R&D roles in oncology/immunology.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Cornerstone revenue driver (61% of portfolio) generating $3.4B annually; provides 10+ years of exclusivity runway.
Help build intelligence for Novartis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Novartis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE asset facing near-term generic erosion; approaching exclusivity cliff in 2026.
Oncology franchise anchor with mid-decade LOE; maintains solid revenue base.
Recent-cycle oncology asset with 10-year exclusivity window; supports diversification beyond ENTRESTO.
Melanoma/NSCLC therapy contributing modestly; faces patent cliff in 2031.
Extended-indication formulation with separate LOE date providing sequential exclusivity.
Immunology franchise player; generic competition active, declining revenue trajectory.
Recent PI3K inhibitor for hormone receptor-positive breast cancer; mid-decade LOE profile.
Neuroscience flagship facing mid-2032 LOE; competes in crowded MS market.
453 discontinued, 223 duplicate formulations not shown
+52 more products with revenue data
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance - BioSpace
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance BioSpace
Novartis ends BioArctic pact; Two VC firms raise inaugural funds - Endpoints News
Novartis ends BioArctic pact; Two VC firms raise inaugural funds Endpoints News
Novartis Exits BrainTransporter Deal with BioArctic 14 Months After Signing - Pharmaceutical Executive
Novartis Exits BrainTransporter Deal with BioArctic 14 Months After Signing Pharmaceutical Executive
Novartis Exits $800M BioArctic Brain-Delivery Pact After 14 Months - BigGo Finance
Novartis Exits $800M BioArctic Brain-Delivery Pact After 14 Months BigGo Finance
Novartis ends BioArctic brain delivery collaboration - The Pharma Letter
Novartis ends BioArctic brain delivery collaboration The Pharma Letter
BioArctic left out in the cold as Novartis walks away from $800M neuro collab - Fierce Biotech
BioArctic left out in the cold as Novartis walks away from $800M neuro collab Fierce Biotech
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in human.
LC-HRMS/MS Characterization of Hydrolytic and Photolytic Degradation Pathways of Ripretinib Following Forced Stress Studies.
+208 more products
Source: state DOL filings, aggregated via Big Local News
Restructuring activity is severe and ongoing; East Hanover-based roles carry elevated churn risk; external candidates should seek role clarity on organizational post-restructuring status and team stability.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo